Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 +/- 22.6% in macro- and 72.8 +/- 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido [1,3,28,29,30].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [30]
In the citing paper
“Further research has reported the recovery of other hormonal axes following adenoma shrinkage (227)”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [227]
Citations
Cites
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Self-citationSex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationColao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Self-citationNew approach to the diagnosis of growth hormone deficiency in adults
Ghigo, E., Aimaretti, G., Gianotti, L., Bellone, J., Arvat, E., & Camanni, F. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340352 · Cited by 257
Di Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Self-citationColao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
Self-citationTreatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
Biller, B. M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2338 · Cited by 216
Cited by
Items 201–260 of 260
Loh, T.-W., Chiu, T., Wu, S., Hung, H., Chen, K.-P., & Su, C. (2011) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2011.08.003 · Cited by 1
Kharb, S., Pandit, A., Garg, M. K., & Brar, K. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.103043 · Cited by 1
Medical Management of Hormone-Secreting Pituitary Tumors
Mathioudakis, N. N., & Salvatori, R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6839-6.10017-6 · Cited by 1
Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment
Oğuz, A., Tüzün, D., Şahin, M., & Gül, K. (2016) · Nigerian Journal of Clinical Practice · doi:10.4103/1119-3077.188693 · Cited by 1
Prolactinomas: Diagnosis and medical treatment
Shimon, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00012-3 · Cited by 1
Gibson, M., & Hammoud, A. O. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6837-0_11 · Cited by 1
Endocrine-Related Sexual Dysfunction in Young People
Talaulikar, V. S., & Sangster, P. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_15 · Cited by 1
Nonsurgical treatment of male infertility: specific therapy
Mills, J. N., & Meacham, R. B. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511635656.025 · Cited by 1
Hipofizės adenomų chirurginio gydymo rezultatus įtakojantys veiksniai
Šinkūnas, K. (2008) · Lithuanian University of Health Sciences · Cited by 1
Alternatives to ovarian hyperstimulation
Aboulghar, M. A., & Rizk, B. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762390.019
Athanasoulia, A. P. (2012) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14553
Role of type I Interferons in the treatment of endocrine and non-endocrine cancers
Vitale, G. (2006) · Università degli Studi di Napoli Federico II · doi:10.6092/unina/fedoa/785
Self-citationVarón de 65 años con cefalea, disminución de la libido y alteraciones de la visión
Rojas‐Marcos, P. M. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70120-4
Melmed, S. K., Casanueva, F. F., Andrew, R. H., David, L. K., Victor, M. M., Janet, A. S., & John, A. W. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-4963
Prolactinomas : clinical studies
Kars, M. (2008) · Leiden Repository (Leiden University)
Mécanismes des dysfonctions et pathologies
Wieacker, P. F., Mahmoud, A., Comhaire, F. H., Depuydt, C., Everaert, K., Ochsendorf, F. R., Colpi, G. M., Mancini, M., Piediferro, G., Scroppo, F. I., et al. (2008) · Springer eBooks · doi:10.1007/978-2-287-72080-2_19
Endocrine Disorders and the Role of Hormone Disrupters
Mahmoud, A., & Comhaire, F. H. (2006) · Springer eBooks · doi:10.1007/3-540-33713-x_64
Pharmacological Treatment for Pituitary Adenomas
Tominaga, A., Kinoshita, Y., Usui, S., & Kurisu, K. (2013) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.22.101
Molitch, M. E. (2008) · Reproductive medicine and assisted reproductive techniques series · doi:10.3109/9780203092200.016
Pituitary Tumor Classification
Tănase, C., Ogrezeanu, I., & Badiu, C. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-415830-6.00001-9
Modern trends in diagnostics and treatment of prolactinomas
Хижняк, О. О., Микитюк, М. Р., & Gogitidze, T. (2013) · Clinical endocrinology and endocrine surgery · doi:10.24026/1818-1384.3(44).2013.77711
Operative Indications and Pitfalls in Patient Selection for Surgery of Pituitary Tumors
Eseonu, C. I., Jackson, C., & Quiñones‐Hinojosa, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56691-7_4
Prolaktinoma’lı Olgularımızın Klinik Değerlendirilmesi
Gökosmanoğlu, F. (2018) · Acta Medica Alanya · doi:10.30565/medalanya.420906
Кирилюк, М. Л. (2018) · Clinical endocrinology and endocrine surgery · doi:10.24026/1818-1384.2(62).2018.135527
The Role of Prolactin and the Diagnostic Value of Hyperprolactinemia in Men
Горпинченко, І. І., & Спиридоненко, В. В. (2019) · Health of Man · doi:10.30841/2307-5090.1.2019.172369
Эффективность супрессивной терапии каберголином у больных молодого возраста с пролактиномой
Хижняк, О. О., Караченцев, Ю. И., Gogitidze, T., & Микитюк, М. Р. (2016) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy
Hyperprolaktinämie: diagnostische Parameter und Therapieverlaufsanalyse eines Patientenkollektivs
Koeck, C. (2017) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Abdalla, M. A. M. (2021) · Open University of Cape Town (University of Cape Town)
Hyperprolactinaemia in a Patient with Acute Ischaemic Stroke
Zain, W. M. S. W., Omar, J., Ismail, T. S. T., & Soh, N. A. A. C. S. C. (2021) · Malaysian Journal of Science Health & Technology · doi:10.33102/mjosht.v7i3.168
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00025-x
(2012) · Folia Endocrinologica Japonica · doi:10.1507/endocrine.88.supplement-2_42
Rizk, B. M., Shammas, N. L., AlBakhit, S., Helvacioglu, A., & Gilmore, S. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781316477021.026
Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma
Rudman, Y., Duskin‐Bitan, H., Masri‐Iraqi, H., Akirov, A., & Shimon, I. (2022) · Endocrine Abstracts · doi:10.1530/endoabs.81.p653
Molitch, M. E. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch14
(2019) · Folia Endocrinologica Japonica · doi:10.1507/endocrine.95.s.hpt_5
Linea guida per la terapia dei prolattinomi
Cozzi, R. C., Auriemma, R. S., Menis, E. D., Esposito, F., Fattori, L., Ferrante, E., Iatì, G., Mazzatenta, D., Poggi, M., Rudà, R., et al. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01327-1
Serum Prolactin Status in Primary Sub-Fertile Males with Azoospermia and Oligozoospermia
Naznin, L., Parveen, T., Giti, S., Khan, A. A., Jasmine, R., & Islam, M. R. (2021) · Journal of Enam Medical College · doi:10.3329/jemc.v11i2.65190
Prolactin Adenomas in Senegal: Epidemiological, Diagnostic and Therapeutic Aspects of 89 Cases
Ndour, M. A., Diédhiou, D., Sow, D., Djiba, B., Dieng, M., Diallo, I., Gadji, F. K., Borges, J., Diembou, M., Ndiaye, F. M., et al. (2023) · Open Journal of Internal Medicine · doi:10.4236/ojim.2023.133022
Evaluation of Treatment Strategies for Male Prolactin-Secreting Pituitary Neuroendocrine Tumors
Saito, N., Hirai, N., Koyahara, Y., Sato, S., Hiramoto, Y., Fujita, S., Nakayama, H., Hayashi, M., & Iwabuchi, S. (2024) · Cureus · doi:10.7759/cureus.54503
Prolactinomas: Clinical manifestations and therapy
Rees, S. E., & Rees, D. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00003-0
Prolactinoma Gigante en una Mujer de 18 Años
Cruz, J. C. B. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i4.12992
When to decide on testosterone replacement despite dopamine agonist therapy in male prolactinomas?
Fukuoka, H. (2024) · Pituitary · doi:10.1007/s11102-024-01457-1
Gupta, P., Shakrawal, N., Sharma, V., Shukla, R. K. G., Garg, M., Kaushal, D., & Goyal, A. (2025) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-025-05406-7
Junger männlicher Patient mit Libidoverlust und erektiler Dysfunktion
Linse, K.-P., & Hartmann, M. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05493-1
The Hypothalamus-Pituitary in Males in Health and Disease
Winters, S. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_7
Seibert, T. A., Shariff, A. I., & McManus, H. D. (2025) · Case Reports in Oncology · doi:10.1159/000548162
Stumpf, M. A. M., Tavares, L. A. G., Queiroz, N. L., Souza, M. N. P., Fortini, I., Marin, I. C., Yamaki, M. L., Cescato, V. Â. S., & Glezer, A. (2025) · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · doi:10.1055/s-0045-1813725
Male Infertility as a Systemic Disease
Negri, F., Langroudi, A. P., Cheng, Y., & Eisenberg, M. L. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_54-1
Beyond normalization: rethinking optimal prolactin levels in prolactinoma management
Puzio, A., Hylińska, M., Kapała, O., & Owecki, M. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2679517
Recovery of the Gonadal Axis in Patients with Prolactinomas
Müller, J. R., Nader-Muller, S., Bullmann, C., Shahla, L., & Harbeck, B. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2886-2899
Tanabe, N., Inoshita, N., Kasuga, E., Matsuoka, G., Ishida, A., Kato, M., Yoshimoto, H., Shiramizu, H., Suga, H., Tateno, T., et al. (2026) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002577
Domínguez, M. A. A., Maya, W. D. C., & Topete, A. M. (2026) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-026-03980-5
Visual field loss in pituitary and hypothalamic disorders
Batra, R., & Alvarez, L. M. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102152
Murhega, R. B., Constantinescu, S. M., Raftopoulos, C., Maiter, D. M., & Fomekong, E. (2026) · Pituitary · doi:10.1007/s11102-026-01749-8
Stumpf, M. A. M., & Glezer, A. (2026) · Endocrine Research · doi:10.1080/07435800.2026.2724843
Coulibaly, M. B., Diarra, A., Sylla, S. D., Traoré, A., Mariko, S., Traore, B., Diallo, M. B., Togo, A., Ongoiba, I., Traoré, A., et al. (2026) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2026.169128
Miki, N., Ono, M., Izumi, S., Hori, T., Abe, K., & Kawamata, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag406
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-9010-2
Meccanismi delle disfunzioni e patologie
Wieacker, P. F., Mahmoud, A., Comhaire, F. H., Depuydt, C., Everaert, K., Ochsendorf, F. R., Colpi, G. M., Mancini, M., Piediferro, G., Scroppo, F. I., et al. (2010) · Springer eBooks · doi:10.1007/978-88-470-1487-9_19
Metadata
- Authors
- Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Colao, Annamaria
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1704-1711
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2091047975
- Semantic Scholar
- 1e7fe5139d0e093e73f435b5c99704ece8f0a0ef
- Cited by
- 256
- References
- 28
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- cabergoline, prolactinoma, macroprolactinoma, microprolactinoma, prolactin normalization, tumor shrinkage, pituitary function recovery, hypogonadism, testosterone, semen quality, sperm count, sperm motility, visual field defects, headache, galactorrhea, hypopituitarism, dopamine agonists
- MeSH terms
- Cabergoline, Adolescent, Adult, Aged, Drug Administration Schedule, Ergolines, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland, Pituitary Neoplasms, Prolactin, Semen, Prolactinoma, Treatment Outcome, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.